Medicus Pharma Ltd (MDCX)
NASDAQ:MDCX
Want to see MDCX full AI Analyst Report?
Top Page
Medicus Pharma Ltd
(NASDAQ:MDCX)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.36
▼(-75.21% Downside)
Action:Reiterated
Date:05/28/26
The score is held down primarily by weak financial performance (no revenue, deepening losses, and sizable cash burn) and elevated financing/dilution risk. Technicals also reflect a weak longer-term trend with soft momentum, while valuation is constrained by negative earnings and no dividend support. Corporate events add additional pressure due to Nasdaq compliance risks and potentially shareholder-dilutive funding actions.
Positive Factors
Modest current leverage
Current low leverage (debt-to-equity ~0.13) gives Medicus structural breathing room versus highly indebted peers, lowering near-term insolvency risk and supporting continued R&D spend. This reduces immediate refinancing urgency and preserves operational flexibility over coming months.
Negative Factors
High cash burn, pre-revenue
Being pre-revenue with TTM operating cash flow around -$25.9M and net losses near -$28.0M means Medicus must repeatedly access external capital to sustain operations. Persistent high burn without product revenue increases dilution risk and compresses the timeline to achieve critical clinical milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Modest current leverage
Current low leverage (debt-to-equity ~0.13) gives Medicus structural breathing room versus highly indebted peers, lowering near-term insolvency risk and supporting continued R&D spend. This reduces immediate refinancing urgency and preserves operational flexibility over coming months.
Read all positive factors
Medicus Pharma Ltd (MDCX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$21.47M
Dividend YieldN/A
Average Volume (3M)6.05M
Price to Earnings (P/E)―
Beta (1Y)1.46
Revenue GrowthN/A
EPS Growth-73.57%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.20
Shares Outstanding56,658,165
10 Day Avg. Volume1,720,334
30 Day Avg. Volume6,054,447
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-391.45
Price to Sales (P/S)0.00
P/FCF Ratio-1.16
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.06
Forecast
1Y Price Target
$5.50Price Target Upside276.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.56
Revenue Forecast (FY)N/A
Medicus Pharma Ltd Business Overview & Revenue Model
Company Description
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer....
How the Company Makes Money
null...
Medicus Pharma Ltd Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
28
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -35.50M | -18.35M | -11.16M | -586.78K | -1.17M | -1.94M |
| Net Income | -36.93M | -25.37M | -11.16M | -5.31M | -1.69M | -2.06M |
Balance Sheet | ||||||
| Total Assets | 7.43M | 10.06M | 5.65M | 1.89M | 282.65K | 78.51K |
| Cash, Cash Equivalents and Short-Term Investments | 6.37M | 8.71M | 4.16M | 1.72M | 267.65K | 78.51K |
| Total Debt | 169.62K | 4.00M | 322.27K | 0.00 | 1.53M | 667.93K |
| Total Liabilities | 6.00M | 10.02M | 2.51M | 781.61K | 12.48M | 10.58M |
| Stockholders Equity | 1.33M | -67.55K | 3.13M | 1.11M | -12.20M | -10.51M |
Cash Flow | ||||||
| Free Cash Flow | -23.41M | -22.78M | -10.25M | -4.16M | -1.06M | -1.45M |
| Operating Cash Flow | -23.41M | -22.78M | -10.25M | -4.16M | -1.06M | -1.45M |
| Investing Cash Flow | -4.65M | -4.62M | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 31.16M | 31.94M | 12.69M | 5.61M | 1.25M | 882.38K |
Medicus Pharma Ltd Technical Analysis
Neutral
1.46
Price Trends
0.36
Positive
0.74
Negative
1.45
Negative
Market Momentum
-0.02
Negative
58.65
Neutral
74.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDCX, the sentiment is Neutral. The current price of 1.46 is above the 20-day moving average (MA) of 0.31, above the 50-day MA of 0.36, and above the 200-day MA of 1.45, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 58.65 is Neutral, neither overbought nor oversold. The STOCH value of 74.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MDCX.
Medicus Pharma Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $509.53M | -8.33 | -22.51% | ― | 1199.64% | 30.81% | |
53 Neutral | $105.61M | -5.38 | -72.68% | ― | ― | 64.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $23.21M | -0.29 | -191.12% | ― | ― | 38.53% | |
44 Neutral | $29.04M | -3.21 | 9999.00% | ― | ― | ― | |
44 Neutral | $103.75M | -1.34 | -59.89% | ― | ― | 44.08% | |
41 Neutral | $21.47M | -0.30 | -4086.31% | ― | ― | -73.57% |
* Healthcare Sector Average
MDCX
Medicus Pharma Ltd
0.38
-2.25
-85.59%
OVID
Ovid Therapeutics
2.73
2.44
844.64%
JSPR
Jasper Therapeutics
0.83
-4.62
-84.79%
CGTX
Cognition Therapeutics
1.18
0.86
268.75%
NRSN
Neurosense Therapeutics Ltd.
0.82
-0.87
-51.42%
PEPG
PepGen Inc.
1.50
0.06
4.17%
Medicus Pharma Ltd Corporate Events
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Medicus Pharma Secures Financing Amid Nasdaq Compliance Pressure
Negative
May 27, 2026
On May 27, 2026, Medicus Pharma Ltd. closed a $22.86 million secured financing with Streeterville Capital via two promissory notes, receiving $12 million in cash and placing $10 million in a controlled deposit account accessible through future not...
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Medicus Pharma Expands ATM Equity Program for Funding
Negative
Apr 24, 2026
On April 23, 2026, Medicus Pharma Ltd. amended its equity distribution arrangement with Maxim Group LLC and Yorkville Securities, LLC to significantly increase its at-the-market equity offering capacity from about $15.35 million to up to $50 milli...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Medicus Pharma Raises Equity Financing, Reduces Yorkville Debenture
Neutral
Mar 6, 2026
Medicus Pharma Ltd. disclosed that, under its Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville) dated February 10, 2025, it sold a total of 4,471,038 common shares to Yorkville between December 19, 2025, and March 6, 2026, for aggr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.